Canadian Know-How: Successfully Navigating a Centralized Framework for Oncology Clinical Trial Ethical Review
Now more than ever, time is of the essence when it comes to oncology clinical trial start-up and execution. The…
Where Are the Phase I and II Oncology Trials in Canada?
For every phase I and II oncology trial taking place in Canada, there are almost 8-fold more phase I and…
Canada: a Region of Choice for Your Study Expansion
Successfully designing and conducting oncology trials is not getting easier. Many of the challenges we are facing in oncology research…
Why Does Your CRO’s Assignment Practice for CRAs Matter?
Monitoring the progress of the research represents a fundamental aspect of successful outcomes by ensuring that constraints to success are…
Does Your Monitoring Vendor Hold the Key to Improving the Quality of Your Database?
This article will discuss how involving your specialized CRO early in the database development phase can reduce the risk of…
Will Canada’s Multi-Center Approval Processes Help Your Oncology Clinical Trial Exceed Pivotal Milestones?
For the Sponsor choosing Canada to help meet and exceed pivotal corporate objectives on their oncology trial, First Site Opened…
Exploring a ‘Rescue’ Strategy for Your Oncology Clinical Trial?
Although not formally defined within the industry, the term ‘rescue’ is commonly linked with clinical trials where enrollment is falling…
Effectively Integrating a Regionally Specialized CRO Team into Your Existing US/Global Study Framework
The expansion of an oncology study to ex-US areas, such as Canada, brings many advantages, including faster patient accrual and…
Key Attributes of First-In-Class Oncology Clinical Trial Sponsors
Key Attributes of First-In-Class Oncology Clinical Trial Sponsors Overcoming Current Industry Challenges through Excellence Current industry trends that increasingly contribute…
Navigating Canadian Regulations for Oncology Clinical Research – Part II
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part II Senior executives from oncology drug developers looking to…